Acorda Therapeutics® is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Acorda’s marketed products include Zanaflex Capsules® (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. Zanaflex Capsules® and Zanaflex are short-acting drugs approved for the management of spasticity. Because of the short duration of effect, treatment should be reserved for those daily activities and times when relief of spasticity is most important. The most frequent adverse events with these products are dry mouth, sedation, asthenia, and dizziness, and are most often considered mild to moderate.

The Company also has a product in clinical development - Fampridine-SR. Acorda recently completed a Phase 3 clinical study of Fampridine-SR in people with all types of MS. Additionally, Acorda is developing multiple approaches to regeneration and repair of the spinal cord and brain.